CHIME survey: IT service model could save $11B

Healthcare providers could reduce costs by nine percent or $11 billion over the next three years through the adoption of IT-as-a-service models, according to a report by the public-private partnership MeriTalk and EMC. The findings are based on a survey of 109 members of the College of Healthcare Information Management Executives (CHIME).

The majority (94 percent) of respondents say they already have purchased at least part of their IT portfolio "as a service," divided up in the following ways: 

  • 87 percent have purchased software or applications as a service, such as virtualization.
  • 22 percent have purchased platforms or complete environments, which can help increase the use of private and hybrid clouds.
  • 18 percent have purchased infrastructure-as-a-service.

While just 15 percent of the respondents' IT portfolios are delivered as a service now, the respondents estimate that 47 percent has the potential to be delivered through private, hybrid or public clouds. Almost one-third (32 percent) expect their portfolios will run on that model in the next three years, according to a release on the survey results.

Ninety percent said they believe IT innovation is key to their organization's success and are doing the following to achieve their goals:

  • 87 percent are deploying virtualization.
  • 73 percent are streamlining IT operations.
  • 48 percent are centralizing IT management.

Their top three goals are achieving Stage 2 Meaningful Use, preparing for accountable care and improving information security.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.